These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 7747316)

  • 21. Risk factors for relapse in human immunodeficiency virus type 1 infected adults with pulmonary tuberculosis.
    Johnson JL; Okwera A; Vjecha MJ; Byekwaso F; Nakibali J; Nyole S; Milberg J; Aisu T; Whalen CC; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):446-53. PubMed ID: 9441100
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A prospective study of the risk of tuberculosis among HIV-infected patients.
    Guelar A; Gatell JM; Verdejo J; Podzamczer D; Lozano L; Aznar E; Miró JM; Mallolas J; Zamora L; González J
    AIDS; 1993 Oct; 7(10):1345-9. PubMed ID: 8267907
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cutaneous hypersensitivity reactions due to thiacetazone in the treatment of tuberculosis in Zambian children infected with HIV-I.
    Chintu C; Luo C; Bhat G; Raviglione M; DuPont H; Zumla A
    Arch Dis Child; 1993 May; 68(5):665-8. PubMed ID: 7686737
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tuberculosis and human immunodeficiency virus infection in developing countries.
    Harries AD
    Lancet; 1990 Feb; 335(8686):387-90. PubMed ID: 1968123
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of HIV on tuberculosis in Zambia: a cross sectional study.
    Elliott AM; Luo N; Tembo G; Halwiindi B; Steenbergen G; Machiels L; Pobee J; Nunn P; Hayes RJ; McAdam KP
    BMJ; 1990 Sep; 301(6749):412-5. PubMed ID: 2282396
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of human immunodeficiency virus 1 infection on clinical presentation, treatment outcome and survival in a cohort of Ethiopian children with tuberculosis.
    Palme IB; Gudetta B; Bruchfeld J; Muhe L; Giesecke J
    Pediatr Infect Dis J; 2002 Nov; 21(11):1053-61. PubMed ID: 12442029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Evidence for heterosexual transmission and clinical manifestations of human immunodeficiency virus infection and related conditions in Lusaka, Zambia.
    Melbye M; Njelesani EK; Bayley A; Mukelabai K; Manuwele JK; Bowa FJ; Clayden SA; Levin A; Blattner WA; Weiss RA
    Lancet; 1986 Nov; 2(8516):1113-5. PubMed ID: 2877269
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk factors for adverse drug reactions during thiacetazone treatment of pulmonary tuberculosis in human immunodeficiency virus infected adults.
    Okwera A; Johnson JL; Vjecha MJ; Wolski K; Whalen CC; Hom D; Huebner R; Mugerwa RD; Ellner JJ
    Int J Tuberc Lung Dis; 1997 Oct; 1(5):441-5. PubMed ID: 9441099
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical course of human immunodeficiency virus type 1 associated pulmonary tuberculosis during short-course antituberculosis therapy.
    Schwander SK; Dietrich M; Mugyenyi P; Kityo C; Okwera A; Johnson J; Nsubuga P; Ruesch-Gerdes S; Whalen C
    East Afr Med J; 1997 Sep; 74(9):543-8. PubMed ID: 9487427
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Modelling the economic benefits of tuberculosis preventive therapy for people with HIV: the example of Zambia.
    Foster S; Godfrey-Faussett P; Porter J
    AIDS; 1997 Jun; 11(7):919-25. PubMed ID: 9189218
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Randomised trial of isoniazid versus rifampicin and pyrazinamide for prevention of tuberculosis in HIV-1 infection.
    Halsey NA; Coberly JS; Desormeaux J; Losikoff P; Atkinson J; Moulton LH; Contave M; Johnson M; Davis H; Geiter L; Johnson E; Huebner R; Boulos R; Chaisson RE
    Lancet; 1998 Mar; 351(9105):786-92. PubMed ID: 9519950
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Albendazole chemotherapy for treatment of diarrhoea in patients with AIDS in Zambia: a randomised double blind controlled trial.
    Kelly P; Lungu F; Keane E; Baggaley R; Kazembe F; Pobee J; Farthing M
    BMJ; 1996 May; 312(7040):1187-91. PubMed ID: 8634560
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Predictors of mortality among HIV-infected women in Kigali, Rwanda.
    Lindan CP; Allen S; Serufilira A; Lifson AR; Van de Perre P; Chen-Rundle A; Batungwanayo J; Nsengumuremyi F; Bogaerts J; Hulley S
    Ann Intern Med; 1992 Feb; 116(4):320-8. PubMed ID: 1733389
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Tuberculosis-related mortality in people living with HIV in Europe and Latin America: an international cohort study.
    Podlekareva DN; Efsen AM; Schultze A; Post FA; Skrahina AM; Panteleev A; Furrer H; Miller RF; Losso MH; Toibaro J; Miro JM; Vassilenko A; Girardi E; Bruyand M; Obel N; Lundgren JD; Mocroft A; Kirk O;
    Lancet HIV; 2016 Mar; 3(3):e120-31. PubMed ID: 26939735
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Resistance to antituberculosis drugs in rural South Africa: rates, patterns, risks, and transmission dynamics.
    Wilkinson D; Pillay M; Davies GR; Sturm AW
    Trans R Soc Trop Med Hyg; 1996; 90(6):692-5. PubMed ID: 9015521
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pneumocystis carinii as a cause of pneumonia in HIV-infected patients in Lusaka, Zambia.
    Machiels G; Urban MI
    Trans R Soc Trop Med Hyg; 1992; 86(4):399-400. PubMed ID: 1440816
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tuberculosis programme changes and treatment outcomes in patients with smear-positive pulmonary tuberculosis in Blantyre, Malawi.
    Harries AD; Nyong'Onya Mbewe L; Salaniponi FM; Nyangulu DS; Veen J; Ringdal T; Nunn P
    Lancet; 1996 Mar; 347(9004):807-9. PubMed ID: 8622340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Effectiveness and problems of PZA-containing 6-month regimen for the treatment of new pulmonary tuberculosis patients].
    Wada M
    Kekkaku; 2001 Jan; 76(1):33-43. PubMed ID: 11211781
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cost-effectiveness and total costs of three alternative strategies for the prevention and management of severe skin reactions attributable to thiacetazone in the treatment of Human Immunodeficiency Virus positive patients with tuberculosis in Kenya.
    van Gorkom J; Kibuga DK
    Tuber Lung Dis; 1996 Feb; 77(1):30-6. PubMed ID: 8733411
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cutaneous manifestations of human immunodeficiency virus in Lusaka, Zambia.
    Hira SK; Wadhawan D; Kamanga J; Kavindele D; Macuacua R; Patil PS; Ansary MA; Macher AM; Perine PL
    J Am Acad Dermatol; 1988 Sep; 19(3):451-7. PubMed ID: 2971691
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.